-
Abe K, Kurata T, Teramoto Y C. Lack of susceptibility of various primates and woodchucks to hepatitis C virus[J]. J Med Primatol, 1993, 22(7-8): 433-434.
-
Afdhal N H. The natural history of hepatitis C[J]. Semin Liver Dis, 2004, 24 Suppl 2(): 3-8.
-
Ahmed A, Keeffe E B. Treatment strategies for chronic hepatitis C: update since the 1997 National Institutes of Health Consensus Development Conference[J]. J Gastroenterol Hepatol, 1999, 14 Suppl(): S12-18.
-
Alter H J, Seeff L B. Recovery, persistence, and sequelae in hepatitis C virus infection: a perspective on long-term outcome[J]. Semin Liver Dis, 2000, 20(1): 17-35. doi: 10.1055/s-2000-9505
-
Alter M J, Margolis H S, Krawczynski K. The natural history of community-acquired hepatitis C in the United States. The Sentinel Counties Chronic non-A, non-B Hepatitis Study Team[J]. N Engl J Med, 1992, 327(27): 1899-1905. doi: 10.1056/NEJM199212313272702
-
Aly H H, Shimotohno K, Hijikata M. 3D cultured immortalized human hepatocytes useful to develop drugs for blood-borne HCV[J]. Biochem Biophys Res Commun, 2009, 379(2): 330-334. doi: 10.1016/j.bbrc.2008.12.054
-
Azuma H, Paulk N, Ranade A. Robust expansion of human hepatocytes in Fah-/-/Rag2-/-/Il2rg-/-mice[J]. Nat Biotechnol, 2007, 25(8): 903-910. doi: 10.1038/nbt1326
-
Bartenschlager R. Hepatitis C virus molecular clones: from cDNA to infectious virus particles in cell culture[J]. Curr Opin Microbiol, 2006, 9(4): 416-422. doi: 10.1016/j.mib.2006.06.012
-
Bartenschlager R, Lohmann V. Replication of hepatitis C virus[J]. J Gen Virol, 2000, 81 Pt 7(): 1631-1648.
-
Bartosch B, Dubuisson J, Cosset F L. Infectious hepatitis C virus pseudo-particles containing functional E1-E2 envelope protein complexes[J]. J Exp Med, 2003, 197(5): 633-642. doi: 10.1084/jem.20021756
-
Bartosch B, Vitelli A, Granier C. Cell entry of hepatitis C virus requires a set of co-receptors that include the CD81 tetraspanin and the SR-B1 scavenger receptor[J]. J Biol Chem, 2003, 278(43): 41624-41630. doi: 10.1074/jbc.M305289200
-
Beames B, Chavez D, Lanford R E. GB virus B as a model for hepatitis C virus[J]. Ilar J, 2001, 42(2): 152-160. doi: 10.1093/ilar.42.2.152
-
Beard M R, Abell G, Honda M. An infectious molecular clone of a Japanese genotype 1b hepatitis C virus[J]. Hepatology, 1999, 30(1): 316-324. doi: 10.1002/(ISSN)1527-3350
-
Behrens S E, Grassmann C W, Thiel H J. Characterization of an autonomous subgenomic pestivirus RNA replicon[J]. J Virol, 1998, 72(3): 2364-2372.
-
Benedicto I, Molina-Jimenez F, Bartosch B. The tight junction-associated protein occludin is required for a postbinding step in hepatitis C virus entry and infection[J]. J Virol, 2009, 83(16): 8012-8020. doi: 10.1128/JVI.00038-09
-
Berger K L, Cooper J D, Heaton N S. Roles for endocytic trafficking and phosphatidylinositol 4-kinase Ⅲ alpha in hepatitis C virus replication[J]. Proc Natl Acad Sci USA, 2009, 106(18): 7577-7582. doi: 10.1073/pnas.0902693106
-
Berger K L, Randall G. Potential roles for cellular cofactors in hepatitis C virus replication complex formation[J]. Commun Integr Biol, 2009, 2(6): 471-473. doi: 10.4161/cib.2.6.9261
-
Bissig K D, Le T T, Woods N B. Repopulation of adult and neonatal mice with human hepatocytes: a chimeric animal model[J]. Proc Natl Acad Sci U S A, 2007, 104(51): 20507-20511. doi: 10.1073/pnas.0710528105
-
Bissig K D, Wieland S F, Tran P. Human liver chimeric mice provide a model for hepatitis B and C virus infection and treatment[J]. J Clin Invest, 2010, (): -.
-
Blanchard E, Belouzard S, Goueslain L. Hepatitis C virus entry depends on clathrin-mediated endocytosis[J]. J Virol, 2006, 80(14): 6964-6972. doi: 10.1128/JVI.00024-06
-
Blight K J, Kolykhalov A A, Rice C M. Efficient initiation of HCV RNA replication in cell culture[J]. Science, 2000, 290(5498): 1972-1975. doi: 10.1126/science.290.5498.1972
-
Blight K J, McKeating J A, Marcotrigiano J. Efficient Replication of Hepatitis C Virus Genotype 1a RNAs in Cell Culture[J]. J Virol, 2003, 77(5): 3181-3190. doi: 10.1128/JVI.77.5.3181-3190.2003
-
Bode J G, Brenndorfer E D, Karthe J. Interplay between host cell and hepatitis C virus in regulating viral replication[J]. Biol Chem, 2009, 390(10): 1013-1032.
-
Boriskin Y S, Leneva I A, Pecheur E I. Arbidol: a broad-spectrum antiviral compound that blocks viral fusion[J]. Curr Med Chem, 2008, 15(10): 997-1005. doi: 10.2174/092986708784049658
-
Boriskin Y S, Pecheur E I, Polyak S J. Arbidol: a broad-spectrum antiviral that inhibits acute and chronic HCV infection[J]. Virol J, 2006, 3(): 56-. doi: 10.1186/1743-422X-3-56
-
Broering T J, Garrity K A, Boatright N K. Identification and characterization of broadly neutralizing human monoclonal antibodies directed against the E2 envelope glycoprotein of hepatitis C virus[J]. J Virol, 2009, 83(23): 12473-12482. doi: 10.1128/JVI.01138-09
-
Buck M. Direct infection and replication of naturally occurring hepatitis C virus genotypes 1, 2, 3 and 4 in normal human hepatocyte cultures[J]. PLoS One, 2008, 3(7): e2660-. doi: 10.1371/journal.pone.0002660
-
Buckwold V E, Beer B E, Donis R O. Bovine viral diarrhea virus as a surrogate model of hepatitis C virus for the evaluation of antiviral agents[J]. Antiviral Res, 2003, 60(1): 1-15. doi: 10.1016/S0166-3542(03)00174-8
-
Bukh J. A critical role for the chimpanzee model in the study of hepatitis C[J]. Hepatology, 2004, 39(6): 1469-1475. doi: 10.1002/(ISSN)1527-3350
-
Bukh J, Pietschmann T, Lohmann V. Mutations that permit efficient replication of hepatitis C virus RNA in Huh-7 cells prevent productive replication in chimpanzees[J]. Proc Natl Acad Sci USA, 2002, 99(22): 14416-14421. doi: 10.1073/pnas.212532699
-
Burioni R, Perotti M, Mancini N. Perspectives for the utilization of neutralizing human monoclonal antibodies as anti-HCV drugs[J]. J Hepatol, 2008, 49(2): 299-300. doi: 10.1016/j.jhep.2008.05.008
-
Cai Z, Cai L, Jiang J. Human serum amyloid A protein inhibits hepatitis C virus entry into cells[J]. J Virol, 2007, 81(11): 6128-6133. doi: 10.1128/JVI.02627-06
-
Chang K, Wang T, Luo G. Proteomics study of the hepatitis C virus replication complex[J]. Methods Mol Biol, 2009, 510(): 185-193. doi: 10.1007/978-1-59745-394-3
-
Chang K S, Cai Z, Zhang C. Replication of hepatitis C virus (HCV) RNA in mouse embryonic fibroblasts: protein kinase R (PKR)-dependent and PKR-independent mechanisms for controlling HCV RNA replication and mediating interferon activities[J]. J Virol, 2006, 80(15): 7364-7374. doi: 10.1128/JVI.00586-06
-
Chockalingam K, Simeon R L, Rice C M. A cell protection screen reveals potent inhibitors of multiple stages of the hepatitis C virus life cycle[J]. Proc Natl Acad Sci U S A, 2010, 107(8): 3764-3769. doi: 10.1073/pnas.0915117107
-
Choi S, Sainz B Jr., Corcoran P. Characterization of increased drug metabolism activity in dimethyl sulfoxide (DMSO)-treated Huh7 hepatoma cells[J]. Xenobiotica, 2009, 39(3): 205-217. doi: 10.1080/00498250802613620
-
Choo Q-L, Kuo G, Weiner A J. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome[J]. Science, 1989, 244(): 359-362. doi: 10.1126/science.2523562
-
Chung R, He W, Saquib A. Hepatitis C virus replication is directly inhibited by IFN-alpha in a full-length binary expression system[J]. Proc Natl Acad Sci USA, 2001, 98(17): 9847-9852. doi: 10.1073/pnas.171319698
-
Davis G L, Nelson D R, Terrault N. A randomized, open-label study to evaluate the safety and pharmacokinetics of human hepatitis C immune globulin (Civacir) in liver transplant recipients[J]. Liver Transpl, 2005, 11(8): 941-949. doi: 10.1002/(ISSN)1527-6473
-
Durantel D. Celgosivir, an alpha-glucosidase Ⅰ inhibitor for the potential treatment of HCV infection[J]. Curr Opin Investig Drugs, 2009, 10(8): 860-870.
-
Einav S, Gerber D, Bryson P D. Discovery of a hepatitis C target and its pharmacological inhibitors by microfluidic affinity analysis[J]. Nat Biotechnol, 2008, 26(9): 1019-1027. doi: 10.1038/nbt.1490
-
Evans M J, von Hahn T, Tscherne D M. Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry[J]. Nature, 2007, 446(7137): 801-805. doi: 10.1038/nature05654
-
Fartoux L, Poujol-Robert A, Guechot J. Insulin resistance is a cause of steatosis and fibrosis progression in chronic hepatitis C[J]. Gut, 2005, 54(7): 1003-1008. doi: 10.1136/gut.2004.050302
-
Feinstone S, Alter H, Dienes H. Non-A, non-B hepatitis in chimpanzees and marmosets[J]. J Infect Dis, 1982, 144(6): 588-598.
-
Feld J J, Hoofnagle J H. Mechanism of action of interferon and ribavirin in treatment of hepatitis C[J]. Nature, 2005, 436(7053): 967-972. doi: 10.1038/nature04082
-
Ferreon J C, Ferreon A C, Li K. Molecular determinants of TRIF proteolysis mediated by the hepatitis C virus NS3/4A protease[J]. J Biol Chem, 2005, 280(21): 20483-20492. doi: 10.1074/jbc.M500422200
-
Flisiak R, Feinman S V, Jablkowski M. The cyclophilin inhibitor Debio 025 combined with PEG IFNalpha2a significantly reduces viral load in treatment-naive hepatitis C patients[J]. Hepatology, 2009, 49(5): 1460-1468. doi: 10.1002/hep.22835
-
Foy E, Li K, Wang C. Regulation of interferon regulatory factor-3 by the hepatitis C virus serine protease[J]. Science, 2003, 300(5622): 1145-1148. doi: 10.1126/science.1082604
-
Galun E, Burakova T, Ketzinel M. Hepatitis C virus viremia in SCID-- > BNX mouse chimera[J]. J Infect Dis, 1995, 172(1): 25-30. doi: 10.1093/infdis/172.1.25
-
Garry R F, Dash S. Proteomics computational analyses suggest that hepatitis C virus E1 and pestivirus E2 envelope glycoproteins are truncated class Ⅱ fusion proteins[J]. Virology, 2003, 307(2): 255-265. doi: 10.1016/S0042-6822(02)00065-X
-
Gastaminza P, Whitten-Bauer C, Chisari F V. Unbiased probing of the entire hepatitis C virus life cycle identifies clinical compounds that target multiple aspects of the infection[J]. Proc Natl Acad Sci USA, 2010, 107(1): 291-296. doi: 10.1073/pnas.0912966107
-
Glue P, Fang J W, Rouzier-Panis R. Pegylated interferon-alpha2b: pharmacokinetics, phar-macodynamics, safety, and preliminary efficacy data. Hepatitis C Intervention Therapy Group.[J]. Clin Pharmacol Ther, 2000, 68(5): 556-567.
-
Goergen B, Jakobs S, Symmons P. Quantitation of HCV-replication using one-step competitive reverse transcription-polymerase chain reaction and a solid phase, colorimetric detection method[J]. J Hepatol, 1994, 21(4): 678-682. doi: 10.1016/S0168-8278(94)80118-5
-
Gosert R, Egger D, Lohmann V. Identification of the hepatitis C virus RNA replication complex in Huh-7 cells harboring subgenomic replicons[J]. J Virol, 2003, 77(9): 5487-5492. doi: 10.1128/JVI.77.9.5487-5492.2003
-
Gottwein J M, Scheel T K, Hoegh A M. Robust hepatitis C genotype 3a cell culture releasing adapted intergenotypic 3a/2a (S52/JFH1) viruses[J]. Gastroenterology, 2007, 133(5): 1614-1626. doi: 10.1053/j.gastro.2007.08.005
-
Gottwein J M, Scheel T K, Jensen T B. Development and characterization of hepatitis C virus genotype 1-7 cell culture systems: role of CD81 and scavenger receptor class B type Ⅰ and effect of antiviral drugs[J]. Hepatology, 2009, 49(2): 364-377. doi: 10.1002/hep.22673
-
Gouttenoire J, Penin F, Moradpour D. Hepatitis C virus nonstructural protein 4B: a journey into unexplored territory[J]. Rev Med Virol, 2010, 20(2): 117-129. doi: 10.1002/rmv.v20:2
-
Griffin S. Inhibition of HCV p7 as a therapeutic target[J]. Curr Opin Investig Drugs, 2010, 11(2): 175-181.
-
Grompe M, Laconi E, Shafritz D. Principles of therapeutic liver repopulation[J]. Semin Liver Dis, 1999, 19(1): 7-14. doi: 10.1055/s-2007-1007093
-
Grove J, Huby T, Stamataki Z. Scavenger receptor BI and BII expression levels modulate hepatitis C virus infectivity[J]. J Virol, 2007, 81(7): 3162-3169. doi: 10.1128/JVI.02356-06
-
Haid S, Pietschmann T, Pecheur E I. Low pH-dependent Hepatitis C Virus Membrane Fusion Depends on E2 Integrity, Target Lipid Composition, and Density of Virus Particles[J]. J Biol Chem, 2009, 284(26): 17657-17667. doi: 10.1074/jbc.M109.014647
-
Heckel J L, Sandgren E P, Degen J L. Neonatal bleeding in transgenic mice expressing urokinase-type plasminogen activator[J]. Cell, 1990, 62(3): 447-456. doi: 10.1016/0092-8674(90)90010-C
-
Helle F, Dubuisson J. Hepatitis C virus entry into host cells[J]. Cell Mol Life Sci, 2008, 65(1): 100-112. doi: 10.1007/s00018-007-7291-8
-
Hezode C, Forestier N, Dusheiko G. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection[J]. N Engl J Med, 2009, 360(18): 1839-1850. doi: 10.1056/NEJMoa0807650
-
Hiraga N, Imamura M, Tsuge M. Infection of human hepatocyte chimeric mouse with genetically engineered hepatitis C virus and its susceptibility to interferon[J]. FEBS Lett, 2007, 581(10): 1983-1987. doi: 10.1016/j.febslet.2007.04.021
-
Hiramatsu N, Dash S, Gerber M. HCV cDNA transfection to HepG2 cells[J]. J Viral Hepat, 1997, 4(Suppl 1): 61-67.
-
Hirowatari Y, Hijikata M, Shimotohno K. A novel method for analysis of viral proteinase activity encoded by hepatitis C virus in cultured cells[J]. Anal Biochem, 1995, 225(1): 113-120. doi: 10.1006/abio.1995.1116
-
Holzer M, Ziegler S, Albrecht B. Identification of terfenadine as an inhibitor of human CD81-receptor HCV-E2 interaction: synthesis and structure optimization[J]. Molecules, 2008, 13(5): 1081-1110. doi: 10.3390/molecules13051081
-
Honda A, Arai Y, Hirota N. Hepatitis C virus structural proteins induce liver cell injury in transgenic mice[J]. J Med Virol, 1999, 59(3): 281-289. doi: 10.1002/(ISSN)1096-9071
-
Hong Z, Beaudet-Miller M, Lanford R E. Generation of transmissible hepatitis C virions from a molecular clone in chimpanzees[J]. Virology, 1999, 256(1): 36-44. doi: 10.1006/viro.1999.9603
-
Hoofnagle J H. Course and outcome of hepatitis C[J]. Hepatology, 2002, 36(5 Suppl 1): S21-29.
-
Hsu M, Zhang J, Flint M. Hepatitis C virus glycoproteins mediate pH-dependent cell entry of pseudotyped retroviral particles[J]. Proc Natl Acad Sci USA, 2003, 100(12): 7271-7276. doi: 10.1073/pnas.0832180100
-
Huang Y, Staschke K, De Francesco R. Phosphorylation of hepatitis C virus NS5A nonstructural protein: a new paradigm for phosphorylation-dependent viral RNA replication?[J]. Virology, 2007, 364(1): 1-9. doi: 10.1016/j.virol.2007.01.042
-
Ikeda M, Abe K, Yamada M. Different anti-HCV profiles of statins and their potential for combination therapy with interferon[J]. Hepatology, 2006, 44(1): 117-125. doi: 10.1002/(ISSN)1527-3350
-
Ikeda M, Yi M, Li K. Selectable subgenomic and genome-length dicistronic RNAs derived from an infectious molecular clone of the HCV-N strain of hepatitis C virus replicate efficiently in cultured Huh7 cells[J]. J Virol, 2002, 76(6): 2997-3006. doi: 10.1128/JVI.76.6.2997-3006.2002
-
Ilan E, Arazi J, Nussbaum O. The hepatitis C virus (HCV)-Trimera mouse: a model for evaluation of agents against HCV[J]. J Infect Dis, 2002, 185(2): 153-161. doi: 10.1086/jid.2002.185.issue-2
-
Iro M, Witteveldt J, Angus A G. A reporter cell line for rapid and sensitive evaluation of hepatitis C virus infectivity and replication[J]. Antiviral Res, 2009, 83(2): 148-155. doi: 10.1016/j.antiviral.2009.04.007
-
Jensen T B, Gottwein J M, Scheel T K. Highly efficient JFH1-based cell-culture system for hepatitis C virus genotype 5a: failure of homologous neutralizing-antibody treatment to control infection[J]. J Infect Dis, 2008, 198(12): 1756-1765. doi: 10.1086/596514
-
Jirasko V, Montserret R, Appel N. Structural and functional characterization of nonstructural protein 2 for its role in hepatitis C virus assembly[J]. J Biol Chem, 2008, 283(42): 28546-28562. doi: 10.1074/jbc.M803981200
-
Jones C T, Murray CL, Eastman D K. Hepatitis C virus p7 and NS2 proteins are essential for production of infectious virus[J]. J Virol, 2007, 81(16): 8374-8383. doi: 10.1128/JVI.00690-07
-
Jopling C L, Yi M, Lancaster A M. Modulation of hepatitis C virus RNA abundance by a liver-specific MicroRNA[J]. Science, 2005, 309(5740): 1577-1581. doi: 10.1126/science.1113329
-
Kapadia S B, Barth H, Baumert T. Initiation of hepatitis C virus infection is dependent on cholesterol and cooperativity between CD81 and scavenger receptor B type I[J]. J Virol, 2007, 81(1): 374-383. doi: 10.1128/JVI.01134-06
-
Karayiannis P, Scheuer P J, Bamber M. Experimental infection of Tamarins with human non-A, non-B hepatitis virus[J]. JMedVirol, 1983, 11(): 251-256.
-
Kato T, Date T, Miyamoto M. Efficient replication of the genotype 2a hepatitis C virus subgenomic replicon[J]. Gastroenterology, 2003, 125(6): 1808-1817. doi: 10.1053/j.gastro.2003.09.023
-
Kato T, Furusaka A, Miyamoto M. Sequence analysis of hepatitis C virus isolated from a fulminant hepatitis patient[J]. J Med Virol, 2001, 64(3): 334-339. doi: 10.1002/(ISSN)1096-9071
-
Kawamura T, Furusaka A, Koziel M J. Transgenic expression of hepatitis C virus structural proteins in the mouse[J]. Hepatology, 1997, 25(4): 1014-1021. doi: 10.1002/(ISSN)1527-3350
-
Keck Z Y, Machida K, Lai M M. Therapeutic control of hepatitis C virus: the role of neutralizing monoclonal antibodies[J]. Curr Top Microbiol Immunol, 2008, 317(): 1-38.
-
Khromykh A A, Westaway E G. Subgenomic replicons of the flavivirus Kunjin: construction and applications[J]. J Virol, 1997, 71(2): 1497-1505.
-
Kneteman N M, Mercer D F. Mice with chimeric human livers: who says supermodels have to be tall?[J]. Hepatology, 2005, 41(4): 703-706. doi: 10.1002/(ISSN)1527-3350
-
Kneteman N M, Toso C. In vivo study of HCV in mice with chimeric human livers[J]. Methods Mol Biol, 2009, 510(): 383-399. doi: 10.1007/978-1-59745-394-3
-
Kneteman N M, Weiner A J, O'Connell J. Anti-HCV therapies in chimeric scid-Alb/uPA mice parallel outcomes in human clinical application[J]. Hepatology, 2006, 43(6): 1346-1353. doi: 10.1002/(ISSN)1527-3350
-
Koike K, Moriya K, Ishibashi K. Expression of hepatitis C virus envelope proteins in transgenic mice[J]. JGenVirol, 1995, 76(): 3031-3038.
-
Kolykhalov A, Mihalik K, Feinstone S. Hepatitis C virus-encoded enzymatic activities and conserved RNA elements in the 3' nontranslated region are essential for virus replication in vivo[J]. J Virol, 2000, 74(4): 2046-2051. doi: 10.1128/JVI.74.4.2046-2051.2000
-
Kolykhalov A A, Agapov E V, Blight K J. Transmission of hepatitis C by intrahepatic inoculation with transcribed RNA[J]. Science, 1997, 277(5325): 570-574. doi: 10.1126/science.277.5325.570
-
Kota S, Scampavia L, Spicer T. A Time-Resolved Fluorescence-Resonance Energy Transfer Assay for Identifying Inhibitors of Hepatitis C Virus Core Dimerization[J]. Assay Drug Dev Technol, 2009, (): -.
-
Koutsoudakis G, Herrmann E, Kallis S. The level of CD81 cell surface expression is a key determinant for productive entry of hepatitis C virus into host cells[J]. J Virol, 2007, 81(2): 588-598. doi: 10.1128/JVI.01534-06
-
Koutsoudakis G, Kaul A, Steinmann E. Characterization of the early steps of hepatitis C virus infection by using luciferase reporter viruses[J]. J Virol, 2006, 80(11): 5308-5320. doi: 10.1128/JVI.02460-05
-
Krieger N, Lohmann V, Bartenschlager R. 2001. Enhancement of hepatitis C virus RNA replication by cell culture-adaptive mutations. J Virol 2001 May; 75 (10): 4614-24, 75 (10): 4614-4624.
-
Kwo P, Lawitz E J, McCone J. HCV SPRINT-1: Boceprevir plus Peginterferon alfa-2b/ Ribavirin for Treatment of Genotype 1 Chronic Hepatitis C in Previously Untreated Patients: 59th Annual Meeting of the American Association for the Study of Liver Diseases, San Francisco, CA[J]. Hepatology, 2008, 48, Suppl 1(4): 1027A-.
-
Lanford R E, Bigger C, Bassett S. The chimpanzee model of hepatitis C virus infections[J]. Ilar J, 2001, 42(2): 117-126. doi: 10.1093/ilar.42.2.117
-
Lanford R E, Hildebrandt-Eriksen E S, Petri A. Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection[J]. Science, 2010, 327(5962): 198-201. doi: 10.1126/science.1178178
-
Lavie M, Voisset C, Vu-Dac N. Serum amyloid A has antiviral activity against hepatitis C virus by inhibiting virus entry in a cell culture system[J]. Hepatology, 2006, 44(6): 1626-1634. doi: 10.1002/hep.v44:6
-
Lavillette D, Bartosch B, Nourrisson D. Hepatitis C virus glycoproteins mediate low pH-dependent membrane fusion with liposomes[J]. J Biol Chem, 2006, 281(7): 3909-3917. doi: 10.1074/jbc.M509747200
-
Lavillette D, Pecheur E I, Donot P. Characterization of fusion determinants points to the involvement of three discrete regions of both E1 and E2 glycoproteins in the membrane fusion process of hepatitis C virus[J]. J Virol, 2007, 81(16): 8752-8765. doi: 10.1128/JVI.02642-06
-
Law M, Maruyama T, Lewis J. Broadly neutralizing antibodies protect against hepatitis C virus quasispecies challenge[J]. Nat Med, 2008, 14(1): 25-27. doi: 10.1038/nm1698
-
Lemm J A, O'Boyle D, 2nd, Liu M. Identification of hepatitis C virus NS5A inhibitors[J]. J Virol, 2010, 84(1): 482-491. doi: 10.1128/JVI.01360-09
-
Lerat H, Honda M, Beard M R. Steatosis and liver cancer in transgenic mice expressing the structural and nonstructural proteins of hepatitis C virus[J]. Gastroenterology, 2002, 122(2): 352-365. doi: 10.1053/gast.2002.31001
-
Li K, Foy E, Ferreon J C. Immune evasion by hepatitis C virus NS3/4A protease-mediated cleavage of the Toll-like receptor 3 adaptor protein TRIF[J]. Proc Natl Acad Sci USA, 2005, 102(8): 2992-2997. doi: 10.1073/pnas.0408824102
-
Li Q, Brass A L, Ng A. A genome-wide genetic screen for host factors required for hepatitis C virus propagation[J]. Proc Natl Acad Sci USA, 2009, 106(38): 16410-16415. doi: 10.1073/pnas.0907439106
-
Li X D, Sun L, Seth R B. Hepatitis C virus protease NS3/4A cleaves mitochondrial antiviral signaling protein off the mitochondria to evade innate immunity[J]. Proc Natl Acad Sci U S A, 2005, 102(49): 17717-17722. doi: 10.1073/pnas.0508531102
-
Liang T J, Rehermann B, Seeff L B. Pathogenesis, natural history, treatment, and prevention of hepatitis C[J]. Ann Intern Med, 2000, 132(4): 296-305. doi: 10.7326/0003-4819-132-4-200002150-00008
-
Lim S P, Soo H M, Tan Y H. Inducible system in human hepatoma cell lines for hepatitis C virus production[J]. Virology, 2002, 303(1): 79-99. doi: 10.1006/viro.2002.1687
-
Lindenbach B D, Evans M J, Syder A J. Complete replication of hepatitis C virus in cell culture[J]. Science, 2005, 309(5734): 623-626. doi: 10.1126/science.1114016
-
Lindenbach B D, Meuleman P, Ploss A. Cell culture-grown hepatitis C virus is infectious in vivo and can be recultured in vitro[J]. Proc Natl Acad Sci USA, 2006, (): -.
-
Liu S, Yang W, Shen L. Tight junction proteins claudin-1 and occludin control hepatitis C virus entry and are downregulated during infection to prevent superinfection[J]. J Virol, 2009, 83(4): 2011-2014. doi: 10.1128/JVI.01888-08
-
Lohmann V, Hoffmann S, Herian U. Viral and cellular determinants of hepatitis C virus RNA replication in cell culture[J]. J Virol, 2003, 77(5): 3007-3019. doi: 10.1128/JVI.77.5.3007-3019.2003
-
Lohmann V, Korner F, Dobierzewska A. Mutations in Hepatitis C Virus RNAs Conferring Cell Culture Adaptation[J]. J Virol, 2001, 75(3): 1437-1449. doi: 10.1128/JVI.75.3.1437-1449.2001
-
Lohmann V, Korner F, Koch J. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line[J]. Science, 1999, 285(5424): 110-113. doi: 10.1126/science.285.5424.110
-
Maeda N, Watanabe M, Okamoto S. Hepatitis C virus infection in human liver tissue engrafted in mice with an infectious molecular clone[J]. Liver Int, 2004, 24(3): 259-267. doi: 10.1111/liv.2004.24.issue-3
-
Masson D, Koseki M, Ishibashi M. Increased HDL cholesterol and apoA-I in humans and mice treated with a novel SR-BI inhibitor[J]. Arterioscler Thromb Vasc Biol, 2009, 29(12): 2054-2060. doi: 10.1161/ATVBAHA.109.191320
-
Matsumura T, Hu Z, Kato T. Amphipathic DNA polymers inhibit hepatitis C virus infection by blocking viral entry[J]. Gastroenterology, 2009, 137(2): 673-681. doi: 10.1053/j.gastro.2009.04.048
-
McHutchison J G, Everson G T, Gordon S C. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection[J]. N Engl J Med, 2009, 360(18): 1827-1838. doi: 10.1056/NEJMoa0806104
-
Meertens L, Bertaux C, Dragic T. Hepatitis C virus entry requires a critical postinternalization step and delivery to early endosomes via clathrin-coated vesicles[J]. J Virol, 2006, 80(23): 11571-11578. doi: 10.1128/JVI.01717-06
-
Mercer D, Schiller D, Elliott J. Hepatitis C virus replication in mice with chimeric human livers[J]. Nat Med, 2001, 7(8): 927-933. doi: 10.1038/90968
-
Meunier J C, Russell R S, Goossens V. Isolation and characterization of broadly neutralizing human monoclonal antibodies to the e1 glycoprotein of hepatitis C virus[J]. J Virol, 2008, 82(2): 966-973. doi: 10.1128/JVI.01872-07
-
Moradpour D, Penin F, Rice C M. Replication of hepatitis C virus[J]. Nat Rev Microbiol, 2007, 5(6): 453-463. doi: 10.1038/nrmicro1645
-
Moriya K, Yotsuyanagi H, Shintani Y. Hepatitis C virus core protein induces hepatic steatosis in transgenic mice[J]. J Gen Virol, 1997, 78(Pt 7): 1527-1531.
-
Murakami Y, Noguchi K, Yamagoe S. Identification of bisindolylmaleimides and indolocarbazoles as inhibitors of HCV replication by tube-capture-RT-PCR[J]. Antiviral Res, 2009, 83(2): 112-117. doi: 10.1016/j.antiviral.2009.03.008
-
Murray E M, Grobler J A, Markel E J. Persistent replication of hepatitis C virus replicons expressing the betalactamase reporter in subpopulations of highly permissive Huh7 cells[J]. J Virol, 2003, 77(5): 2928-2935. doi: 10.1128/JVI.77.5.2928-2935.2003
-
Myung J, Khalap N, Kalkeri G. Inducible model to study negative strand RNA synthesis and assembly of hepatitis C virus from a full-length cDNA clone[J]. J Virol Methods, 2001, 94(1-2): 55-67. doi: 10.1016/S0166-0934(01)00278-6
-
Nahmias Y, Goldwasser J, Casali M. Apolipoprotein B-dependent hepatitis C virus secretion is inhibited by the grapefruit flavonoid naringenin[J]. Hepatology, 2008, 47(5): 1437-1445. doi: 10.1002/hep.22197
-
Nakabayashi H, Taketa K, Miyano K. Growth of human hepatoma cells lines with differentiated functions in chemically defined medium[J]. Cancer Res, 1982, 42(9): 3858-3863.
-
Noto H, Raskin P. Hepatitis C infection and diabetes[J]. J Diabetes Complications, 2006, 20(2): 113-120. doi: 10.1016/j.jdiacomp.2006.01.001
-
Paeshuyse J, Kaul A, De Clercq E. The non-immunosuppressive cyclosporin DEBIO-025 is a potent inhibitor of hepatitis C virus replication in vitro[J]. Hepatology, 2006, 43(4): 761-770. doi: 10.1002/(ISSN)1527-3350
-
Pan K L, Lee J C, Sung H W. Development of NS3/4A protease-based reporter assay suitable for efficiently assessing hepatitis C virus infection[J]. Antimicrob Agents Chemother, 2009, 53(11): 4825-4834. doi: 10.1128/AAC.00601-09
-
Pasquinelli C, Shoenberger J M, Chung J. Hepatitis C virus core and E2 protein expression in transgenic mice[J]. Hepatology, 1997, 25(3): 719-727. doi: 10.1002/(ISSN)1527-3350
-
Pecheur E I, Lavillette D, Alcaras F. Biochemical mechanism of hepatitis C virus inhibition by the broad-spectrum antiviral arbidol[J]. Biochemistry, 2007, 46(20): 6050-6059. doi: 10.1021/bi700181j
-
Pietschmann T, Kaul A, Koutsoudakis G. Construction and characterization of infectious intra-genotypic and intergenotypic hepatitis C virus chimeras[J]. Proc Natl Acad Sci USA, 2006, 103(19): 7408-7413. doi: 10.1073/pnas.0504877103
-
Pietschmann T, Zayas M, Meuleman P. Production of infectious genotype 1b virus particles in cell culture and impairment by replication enhancing mutations[J]. PLoS Pathog, 2009, 5(6): e1000475-. doi: 10.1371/journal.ppat.1000475
-
Pileri P, Uematsu Y, Campagnoli S. Binding of hepatitis C virus to CD81[J]. Science, 1998, 282(5390): 938-941. doi: 10.1126/science.282.5390.938
-
Ploss A, Evans M J, Gaysinskaya V A. Human occludin is a hepatitis C virus entry factor required for infection of mouse cells[J]. Nature, 2009, 457(7231): 882-886. doi: 10.1038/nature07684
-
Ploss A, Khetani S R, Jones C T. Persistent hepatitis C virus infection in microscale primary human hepatocyte cultures[J]. Proc Natl Acad Sci USA, 2010, 107(7): 3141-3145. doi: 10.1073/pnas.0915130107
-
Ploss A, Rice C M. Towards a small animal model for hepatitis C[J]. EMBO Rep, 2009, 10(11): 1220-1227. doi: 10.1038/embor.2009.223
-
Popescu C I, Dubuisson J. Role of lipid metabolism in hepatitis C virus assembly and entry[J]. Biol Cell, 2009, 102(1): 63-74.
-
Poynard T, Yuen M F, Ratziu V. Viral hepatitis C[J]. Lancet, 2003, 362(9401): 2095-2100. doi: 10.1016/S0140-6736(03)15109-4
-
Prabhu R, Joshi V, Garry R F. Interferon alpha-2b inhibits negative-strand RNA and protein expression from full-length HCV1a infectious clone[J]. Exp Mol Pathol, 2004, 76(3): 242-252. doi: 10.1016/j.yexmp.2004.01.004
-
Reisner Y, Dagan S. The Trimera mouse: generating human monoclonal antibodies and an animal model for human diseases[J]. Trends Biotechnol, 1998, 16(6): 242-246. doi: 10.1016/S0167-7799(98)01203-7
-
Romero-Gomez M. Hepatitis C and insulin resistance: steatosis, fibrosis and non-response[J]. Rev Esp Enferm Dig, 2006, 98(8): 605-615.
-
Romero-Gomez M. Insulin resistance and hepatitis C[J]. World J Gastroenterol, 2006, 12(44): 7075-7080. doi: 10.3748/wjg.v12.i44.7075
-
Sainz B Jr., Barretto N, Uprichard S L. Hepatitis C Virus infection in phenotypically distinct Huh7 cell lines[J]. PLoS ONE, 2009, 4(8): e6561-. doi: 10.1371/journal.pone.0006561
-
Sainz B, J r., Chisari F V. Production of infectious hepatitis C virus by well-differentiated, growth-arrested human hepatoma-derived cells[J]. J Virol, 2006, 80(20): 10253-10257. doi: 10.1128/JVI.01059-06
-
Sainz B, Jr , TenCate V, Uprichard S L. Three-dimensional Huh7 cell culture system for the study of Hepatitis C virus infection[J]. Virol J, 2009, 6(): 103-. doi: 10.1186/1743-422X-6-103
-
Sarrazin C, Rouzier R, Wagner F. SCH 503034, a novel hepatitis C virus protease inhibitor, plus pegylated interferon alpha-2b for genotype 1 nonresponders[J]. Gastroenterology, 2007, 132(4): 1270-1278. doi: 10.1053/j.gastro.2007.01.041
-
Scarselli E, Ansuini H, Cerino R. The human scavenger receptor class B type Ⅰ is a novel candidate receptor for the hepatitis C virus[J]. Embo J, 2002, 21(19): 5017-5025. doi: 10.1093/emboj/cdf529
-
Schaller T, Appel N, Koutsoudakis G. Analysis of hepatitis C virus superinfection exclusion by using novel fluorochrome gene-tagged viral genomes[J]. J Virol, 2007, 81(9): 4591-4603. doi: 10.1128/JVI.02144-06
-
Scheel T K, Gottwein J M, Jensen T B. Development of JFH1-based cell culture systems for hepatitis C virus genotype 4a and evidence for cross-genotype neutralization[J]. Proc Natl Acad Sci USA, 2008, 105(3): 997-1002. doi: 10.1073/pnas.0711044105
-
Schinazi R, Ilan E, Black P. Cell-based and animal models for hepatitis B and C viruses[J]. Antivir Chem Chemother, 1999, 10(3): 99-114. doi: 10.1177/095632029901000301
-
Steinmann E, Whitfield T, Kallis S. Antiviral effects of amantadine and iminosugar derivatives against hepatitis C virus[J]. Hepatology, 2007, 46(2): 330-338.
-
Sulkowski M S. Specific targeted antiviral therapy for hepatitis C[J]. Curr Gastroenterol Rep, 2007, 9(1): 5-13. doi: 10.1007/s11894-008-0015-x
-
Suzuki T, Aizaki H, Murakami K. Molecular biology of hepatitis C virus[J]. J Gastroenterol, 2007, 42(6): 411-423. doi: 10.1007/s00535-007-2030-3
-
Tai A W, Benita Y, Peng L F. A functional genomic screen identifies cellular cofactors of hepatitis C virus replication[J]. Cell Host Microbe, 2009, 5(3): 298-307. doi: 10.1016/j.chom.2009.02.001
-
Tencate V, Sainz B J, Cotler S, et al. 2010. Potential treatment options and future research to increase hepatitis C virus treatment response rate. Hepatic Medicine: Evidence and Research, in press.
-
Trotard M, Lepere-Douard C, Regeard M. Kinases required in hepatitis C virus entry and replication highlighted by small interference RNA screening[J]. Faseb J, 2009, 23(11): 3780-3789. doi: 10.1096/fj.09-131920
-
Tscherne D M, Jones C T, Evans M J. Time-and temperature-dependent activation of hepatitis C virus for low-pH-triggered entry[J]. J Virol, 2006, 80(4): 1734-1741. doi: 10.1128/JVI.80.4.1734-1741.2006
-
Uprichard S L, Chung J, Chisari F V. Replication of a hepatitis C virus replicon clone in mouse cells[J]. Virol J, 2006, 3(): 89-. doi: 10.1186/1743-422X-3-89
-
von Hahn T, Rice C M. Hepatitis C virus entry[J]. J Biol Chem, 2008, 283(7): 3689-3693. doi: 10.1074/jbc.R700024200
-
Wakita T, Pietschmann T, Kato T. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome[J]. Nat Med, 2005, 11(7): 791-796. doi: 10.1038/nm1268
-
Wang C, Gale M Jr., Keller B C. Identification of FBL2 as a geranylgeranylated cellular protein required for hepatitis C virus RNA replication[J]. Mol Cell, 2005, 18(4): 425-434. doi: 10.1016/j.molcel.2005.04.004
-
Watanabe T, Katagiri J, Kojima H. Studies on transmission of human non-A, non-B hepatitis to marmosets[J]. J Med Virol, 1987, 22(): 143-156. doi: 10.1002/(ISSN)1096-9071
-
Welsch S, Miller S, Romero-Brey I. Composition and three-dimensional architecture of the dengue virus replication and assembly sites[J]. Cell Host Microbe, 2009, 5(4): 365-375. doi: 10.1016/j.chom.2009.03.007
-
Williams R. Global challenges in liver disease[J]. Hepatology, 2006, 44(3): 521-526. doi: 10.1002/(ISSN)1527-3350
-
Wolk B, Buchele B, Blum H E, et al. A dynamic view of hepatitis C virus replication complexes. Presented at the 11th International Symposium on HCV and related viruses; 2004, Heidelberg, Germany.
-
Wu G Y, Konishi M, Walton C M. A novel immunocompetent rat model of HCV infection and hepatitis[J]. Gastroenterology, 2005, 128(5): 1416-1423. doi: 10.1053/j.gastro.2005.03.015
-
Wunschmann S, Medh J D, Klinzmann D. Characterization of hepatitis C virus (HCV) and HCV E2 interactions with CD81 and the low-density lipoprotein receptor[J]. J Virol, 2000, 74(21): 10055-10062. doi: 10.1128/JVI.74.21.10055-10062.2000
-
Xie Z, Riezu-Boj J, Lasarte J. Transmission of hepatitis C virus infection to tree shrews[J]. Virology, 1998, 244(2): 513-520. doi: 10.1006/viro.1998.9127
-
Yanagi M, Purcell R H, Emerson S U. Hepatitis C virus: an infectious molecular clone of a second major genotype (2a) and lack of viability of intertypic 1a and 2a chimeras[J]. Virology, 1999, 262(1): 250-263. doi: 10.1006/viro.1999.9889
-
Yanagi M, Purcell R H, Emerson S U. Transcripts from a single full-length cDNA clone of hepatitis C virus are infectious when directly transfected into the liver of a chimpanzee[J]. Proc Natl Acad Sci USA, 1997, 94(16): 8738-8743. doi: 10.1073/pnas.94.16.8738
-
Yanagi M, St Claire M, Emerson S U. In vivo analysis of the 3' untranslated region of the hepatitis C virus after in vitro mutagenesis of an infectious cDNA clone[J]. Proc Natl Acad Sci USA, 1999, 96(5): 2291-2295. doi: 10.1073/pnas.96.5.2291
-
Yanagi M, St Claire M, Shapiro M. Transcripts of a chimeric cDNA clone of hepatitis C virus genotype 1b are infectious in vivo[J]. Virology, 1998, 244(1): 161-172. doi: 10.1006/viro.1998.9092
-
Yang J P, Zhou D, Wong-Staal F. Screening of small-molecule compounds as inhibitors of HCV entry[J]. Methods Mol Biol, 2009, 510(): 295-304. doi: 10.1007/978-1-59745-394-3
-
Ye J, Wang C, Sumpter R Jr.. Disruption of hepatitis C virus RNA replication through inhibition of host protein geranylgeranylation[J]. Proc Natl Acad Sci U S A, 2003, 100(26): 15865-15870. doi: 10.1073/pnas.2237238100
-
Yi M, Bodola F, Lemon S M. Subgenomic hepatitis C virus replicons inducing expression of a secreted enzymatic reporter protein[J]. Virology, 2002, 304(2): 197-210. doi: 10.1006/viro.2002.1652
-
Yi M, Lemon S. Replication of subgenomic hepatitis A virus RNAs expressing firefly luciferase is enhanced by mutations associated with adaptation of virus to growth in cultured cells[J]. J Virol, 2002, 76(3): 1171-1180. doi: 10.1128/JVI.76.3.1171-1180.2002
-
Yi M, Villanueva R A, Thomas D L. Production of infectious genotype 1a hepatitis C virus (Hutchinson strain) in cultured human hepatoma cells[J]. Proc Natl Acad Sci USA, 2006, 103(7): 2310-2315. doi: 10.1073/pnas.0510727103
-
Yoo B J, Selby M J, Choe J. Transfection of a differentiated human hepatoma cell line (Huh7) with in vitro-transcribed hepatitis C virus (HCV) RNA and establishment of a long-term culture persistently infected with HCV[J]. J Virol, 1995, 69(1): 32-38.
-
Yu X, Sainz B Jr., Uprichard S L. Development of a cell-based hepatitis C virus infection fluorescent resonance energy transfer assay for high-throughput antiviral compound screening[J]. Antimicrob Agents Chemother, 2009, 53(10): 4311-4319. doi: 10.1128/AAC.00495-09
-
Zeisel M B, Barth H, Schuster C. Hepatitis C virus entry: molecular mechanisms and targets for antiviral therapy[J]. Front Biosci, 2009, 14(): 3274-3285.
-
Zeisel M B, Koutsoudakis G, Schnober E K. Scavenger receptor class B type Ⅰ is a key host factor for hepatitis C virus infection required for an entry step closely linked to CD81[J]. Hepatology, 2007, 46(6): 1722-1731. doi: 10.1002/hep.v46:6
-
Zhang Y, Weady P, Duggal R. Novel chimeric genotype 1b/2a hepatitis C virus suitable for high-throughput screening[J]. Antimicrob Agents Chemother, 2008, 52(2): 666-674. doi: 10.1128/AAC.01133-07
-
Zhao X, Tang Z, Klumpp B. Primary hepatocytes of Tupaia belangeri as a potential model for hepatitis C virus infection[J]. J Clin Invest, 2002, 109(2): 221-232. doi: 10.1172/JCI0213011
-
Zhong J, Gastaminza P, Cheng G. Robust hepatitis C virus infection in vitro[J]. Proc Natl Acad Sci USA, 2005, 102(26): 9294-9299. doi: 10.1073/pnas.0503596102
-
Zhu H, Elyar J, Foss R. Primary human hepatocyte culture for HCV study[J]. Methods Mol Biol, 2009, 510(): 373-382. doi: 10.1007/978-1-59745-394-3